AP-HP, Department of Hepatology, Groupe Henri-Mondor Albert-Chenevier, Creteil, France.
Liver Int. 2011 Jul;31(6):792-801. doi: 10.1111/j.1478-3231.2010.02425.x. Epub 2011 Mar 31.
To generate a new score with improved accuracy compared with Milan criteria to select patients.
The training cohort comprised 373 patients transplanted for hepatocellular carcinoma (HCC) between 1988 and 1998 (cohort 1). An algorithm was derived from the analysis of patient data by the proportional hazard Cox regression model. The area under the receiver operating characteristic (AUROC) was used to determine a cut-off value. The validation cohort comprised 140 patients transplanted between 1999 and 2001 (cohort 2).
Multivariate analysis identified three predictors of 5-year tumour-free survival: tumour differentiation (P=0.02), diameter (P<0.0001) and number of nodules (P=0.04). A cut-off value of 4 was derived from the AUROC of the final score. Five-year tumour-free survival was 60.2 ± 3.1% in patients with as score <4 and 36.4 ± 4.7% in individuals with a score ≥4, P<0.0001. In the validation cohort, 5-year tumour-free survival was 82.8 ± 3.6% (score <4) and 50.0 ± 10.7% (score ≥4), P=0.0003. In patients with a score <4, there was no significant difference in 5-year tumour-free survival between Milan+ and Milan- patients, either in cohort 1 or 2. Five-year tumour-free survival of Milan- patients was significantly better in individuals with a score <4 compared with those with a score ≥4, both in cohort 1 (61.5 ± 9.1 vs 31.4 ± 4.6%, P=0.009) and in cohort 2 (P=0.02).
A novel score taking into account tumour differentiation shows higher accuracy than Milan criteria in predicting 5-year tumour-free survival following liver transplantation for HCC. Prospective studies should validate these findings.
生成一个与米兰标准相比具有更高准确性的新评分,以选择患者。
训练队列包括 1988 年至 1998 年间移植的 373 例肝细胞癌(HCC)患者(队列 1)。通过比例风险 Cox 回归模型对患者数据进行分析,得出了一个算法。使用接受者操作特征(ROC)曲线下的面积(AUROC)来确定截止值。验证队列包括 1999 年至 2001 年间移植的 140 例患者(队列 2)。
多变量分析确定了 5 年无肿瘤生存率的三个预测因素:肿瘤分化(P=0.02)、直径(P<0.0001)和结节数(P=0.04)。从最终评分的 AUROC 得出 4 分的截止值。评分<4 的患者 5 年无肿瘤生存率为 60.2±3.1%,评分≥4 的患者为 36.4±4.7%,P<0.0001。在验证队列中,5 年无肿瘤生存率分别为 82.8±3.6%(评分<4)和 50.0±10.7%(评分≥4),P=0.0003。在评分<4 的患者中,米兰+和米兰-患者的 5 年无肿瘤生存率在队列 1 和 2 中均无显著差异。在评分<4 的患者中,米兰-患者的 5 年无肿瘤生存率明显优于评分≥4 的患者,在队列 1(61.5±9.1 比 31.4±4.6%,P=0.009)和队列 2(P=0.02)中均如此。
考虑肿瘤分化的新评分在预测 HCC 患者肝移植后 5 年无肿瘤生存率方面比米兰标准具有更高的准确性。前瞻性研究应验证这些发现。